1. |
Reitsma PH, Rosendaal FR. Activation of innate immunity in patients with venous thrombosis: the Leiden Thrombophilia Study [J]. J Thromb Haemost, 2004; 2(4)∶619.
|
2. |
Fichtlscherer S, Breuer S, Heeschen C, et al. Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease [J]. J Am Coll Cardiol, 2004; 44(1)∶44.
|
3. |
Roumen-Klappe EM, den Heijer M, van Uum SH, et al. Inflammatory response in the acute phase of deep vein thrombosis [J]. J Vasc Surg, 2002; 35(4)∶701.
|
4. |
Suwa T, Hogg JC, Quinlan KB, et al. The effect of interleukin-6 on L-selectin levels on polymorphonuclear leukolytes [J]. Am J Physiol Heart Circ Physiol, 2002; 283(3)∶H879.
|
5. |
Min W, Bradley JR, Galbraith JJ, et al. The N-terminal domains target TNF receptor-associated factor-2 to the nucleus and display transcriptional regulatory activity [J]. J Immunol, 1998; 161(1)∶319.
|
6. |
Eppihimer MJ, Schaub RG. P-Selectin-dependent inhibition of thrombosis during venous stasis [J].Arterioscler Thromb Vasc Biol, 2000; 20(11)∶2483.
|
7. |
Henke PK, Wakefield TW, Kadell AM, et al. Interleukin-8 administration enhances venous thrombosis resolution in a rat model [J]. J Surg Res, 2001; 99(1)∶84.
|
8. |
Myers DD Jr, Hawley AE, Farris DM, et al. Cellular IL-10 is more effective than viral IL-10 in decreasing venous thrombosis [J]. J Surg Res, 2003; 112(2)∶168.
|
9. |
Cassatella MA, Gasperini S, Bovolenta C, et al. Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation [J]. Blood, 1999; 94(8)∶2880.
|
10. |
van Haelst PL, Tervaert JW, Bijzet J, et al. Circulating monocytes in patients with acute coronary syndromes lack sufficient interleukin-10 production after lipopolysaccharide stimulation [J]. Clin Exp Immunol, 2004; 138(2)∶364.
|